SD of the mean INR, percentage of INRs > 5.0, and percentage of time in range in relation to CYP2C9 genotype in patients with a target INR of 2.5
| Genotype . | No. . | Mean INR . | SD . | % of high INRs . | % of INRs in range . |
|---|---|---|---|---|---|
| Wild type | 392 | 2.55 | 0.85 | 19.0 | 68.9 |
| 2C9*2 heterozygote | 107 | 2.54 | 0.82 | 20.7 | 68.3 |
| 2C9*2 homozygote | 3 | 2.64 | 0.88 | 30.1 | 64.5 |
| 2C9*3 heterozygote | 53 | 2.49 | 0.76 | 19.5 | 66.8 |
| 2C9*3 homozygote | 0 | — | — | — | — |
| 2C9*2*3 compound heterozygote | 6 | 2.57 | 0.75 | 20.7 | 62.6 |
| Genotype . | No. . | Mean INR . | SD . | % of high INRs . | % of INRs in range . |
|---|---|---|---|---|---|
| Wild type | 392 | 2.55 | 0.85 | 19.0 | 68.9 |
| 2C9*2 heterozygote | 107 | 2.54 | 0.82 | 20.7 | 68.3 |
| 2C9*2 homozygote | 3 | 2.64 | 0.88 | 30.1 | 64.5 |
| 2C9*3 heterozygote | 53 | 2.49 | 0.76 | 19.5 | 66.8 |
| 2C9*3 homozygote | 0 | — | — | — | — |
| 2C9*2*3 compound heterozygote | 6 | 2.57 | 0.75 | 20.7 | 62.6 |
There was no difference between patients grouped according to polymorphism for any parameter.